---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-024731"
form_type: "8-K"
ticker: "ACXP"
cik: "0001736243"
company_name: "Acurx Pharmaceuticals, Inc."
filed_at: "2025-03-18T23:59:59+00:00"
generated_at: "2026-05-24T14:03:23.124329+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Acurx Pharma reports FY 2024 net loss $14.1M; cash $3.7M; EMA guidance for Phase 3

## Summary
- Net loss Q4 2024 $2.8M ($0.16/diluted share) vs $5.1M ($0.37) in Q4 2023; FY 2024 net loss $14.1M ($0.87) vs $14.6M ($1.15).
- Cash at Dec 31, 2024: $3.7M, down from $7.5M; raised $6.6M via ATM in 2024 plus $3.6M in direct offerings in early 2025.
- Positive EMA guidance for ibezapolstat Phase 3 program aligned with FDA; regulatory pathway for MAA after Phase 3 completion.
- Japan patent granted for DNA pol IIIC inhibitors (expires 2039); advancing ACX-375C for MRSA/VRE/Anthrax.
- Phase 2 data: 96% clinical cure, 100% sustained cure at 1 month; non-clinical studies show microbiome-restorative potential.

## SEC filing metadata
- accession: 0001104659-25-024731
- form_type: 8-K
- ticker: ACXP
- cik: 0001736243
- company_name: Acurx Pharmaceuticals, Inc.
- filed_at: 2025-03-18T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1736243/000110465925024731/0001104659-25-024731-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1736243/000110465925024731/tm259528d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-024731
- JSON: https://secwatch.observer/filing/0001104659-25-024731.json
- Plain text: https://secwatch.observer/filing/0001104659-25-024731.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.